The Gut Microbiota in Prediabetes and Diabetes: A Population-Based Cross-Sectional Study

MICROBIOTE
publié le 190720 | par Yedid Diana , DyD Integrative Medic | mis à jour le 210720
source → lien web

The link between the gut microbiota and type 2 diabetes (T2D) warrants further investigation because of known confounding effects from antidiabetic treatment. Here, we profiled the gut microbiota in a discovery (n = 1,011) and validation (n = 484) cohort comprising Swedish subjects naive for diabetes treatment and grouped by glycemic status.

We observed that overall gut microbiota composition was altered in groups with impaired glucose tolerance, combined glucose intolerance and T2D, but not in those with impaired fasting glucose. In addition, the abundance of several butyrate producers and functional potential for butyrate production were decreased both in prediabetes and T2D groups.

Multivariate analyses and machine learning microbiome models indicated that insulin resistance was strongly associated with microbial variations.

Therefore, our study indicates that the gut microbiota represents an important modifiable factor to consider when developing precision medicine approaches for the prevention and/or delay of T2D.


REFERENCES
1. Abdul-Ghani, M.A., Lyssenko, V., Tuomi, T., DeFronzo, R.A., and Groop, L. (2009). Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study. Diabetes Care 32, 281'286.
2. Abdul-Ghani, M.A., Tripathy, D., and DeFronzo, R.A. (2006). Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29,1130'1139.
3. Ahlqvist, E., Storm, P., Kar ' aj ' am' aki, A., Martinell, M., Dorkhan, M., Carlsson, A., 'Vikman, P., Prasad, R.B., Aly, D.M., Almgren, P., et al. (2018). Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 6, 361'369.
4. Albarracin, C.A., Fuqua, B.C., Evans, J.L., and Goldfine, I.D. (2008). Chromium picolinate and biotin combination improves glucose metabolism in treated, un-controlled overweight to obese patients with type 2 diabetes. Diabetes Metab.Res. Rev. 24, 41'51.
5. Alberti, K.G., and Zimmet, P.Z. (1998). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15,539'553.
6. Allin, K.H., Tremaroli, V., Caesar, R., Jensen, B.A.H., Damgaard, M.T.F., Bahl,M.I., Licht, T.R., Hansen, T.H., Nielsen, T., Dantoft, T.M., et al. (2018). Aberrant intestinal microbiota in individuals with prediabetes. Diabetologia 61, 810'820.
7. Backhed, F., Ding, H., Wang, T., Hooper, L.V., Koh, G.Y., Nagy, A., 'Semenkovich, C.F., and Gordon, J.I. (2004). The gut microbiota as an
environ-mental factor that regulates fat storage. Proc. Natl. Acad. Sci. USA 101,15718'15723.
8. Bergstro ' m, G., Berglund, G., Blomberg, A., Brandberg, J., Engstro ' m, G.,Engvall, J., Eriksson, M., de Faire, U., Flinck, A., Hansson, M.G., et al.(2015). The Swedish cardiopulmonary BioImage study: objectives and design.J. Intern. Med. 278, 645'659.
9. Camacho, C., Coulouris, G., Avagyan, V., Ma, N., Papadopoulos, J., Bealer,K., and Madden, T.L. (2009). Blast+: architecture and applications. BMC Bioinformatics 10, 421.
10. Canfora, E.E., Meex, R.C.R., Venema, K., and Blaak, E.E. (2019). Gut microbial metabolites in obesity, NAFLD and T2DM. Nat. Rev. Endocrinol. 15, 261'273.

Services du Dr Richard Haddad | Paris, France | designed and powered by myShap.com
Services du Dr Richard Haddad | Paris, France | designed and powered by myShap.com
Services du Dr Richard Haddad | Paris, France | designed and powered by myShap.com
LANGUES